WO2025154020 - IMPROVED GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/154020
Publication Date
24.07.2025
International Application No.
PCT/IB2025/050535
International Filing Date
17.01.2025
Title **
[English]
IMPROVED GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS PEPTIDIQUES AGONISTES DU RÉCEPTEUR GIP AMÉLIORÉS ET LEURS UTILISATIONS
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
COLLIS, Leon
HENNIOT, Antoine
FALK, Matthew
SCORAH, Nicholas
Priority Data
63/622,637
19.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6437 | |
| EPO | Filing, Examination, Granting | 115854 | |
| Japan | Filing, Examination, Granting | 4954 | |
| South Korea | Filing, Examination, Granting | 7989 | |
| USA | Filing, Examination, Granting | 28940 |
Total:
164,174
Contact Us
Abstract[English]
The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis while having an improved profile.[French]
La présente divulgation concerne des composés peptidiques agonistes du récepteur GIP appropriés à un dosage d'une fois par semaine (QW), lesdits composés peptidiques ayant une action d’activation sur les récepteurs GIP et l’utilisation du peptide agoniste du récepteur GIP en tant que médicament pour le traitement et/ou la prévention de vomissements ou d'un symptôme ou d'un trouble associés aux vomissements tout en ayant un profil amélioré.